Table of Content

1 Report Overview
1.1 Primary Biliary Cirrhosis Drug Definition
1.2 Market by Type
1.2.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Budesonide
1.2.3 FFP-104
1.2.4 GSK-2330672
1.2.5 MBX-8025
1.2.6 NGM-282
1.2.7 Others
1.3 Market Segment by Application
1.3.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Primary Biliary Cirrhosis Drug Sales
2.1 Global Primary Biliary Cirrhosis Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Primary Biliary Cirrhosis Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Primary Biliary Cirrhosis Drug Revenue by Region
2.3.1 Global Primary Biliary Cirrhosis Drug Revenue by Region (2018-2023)
2.3.2 Global Primary Biliary Cirrhosis Drug Revenue by Region (2024-2034)
2.4 Global Primary Biliary Cirrhosis Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Primary Biliary Cirrhosis Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Primary Biliary Cirrhosis Drug Sales Quantity by Region
2.6.1 Global Primary Biliary Cirrhosis Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Primary Biliary Cirrhosis Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Primary Biliary Cirrhosis Drug Sales Quantity by Manufacturers
3.1.1 Global Primary Biliary Cirrhosis Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Primary Biliary Cirrhosis Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Primary Biliary Cirrhosis Drug Sales in 2024
3.2 Global Primary Biliary Cirrhosis Drug Revenue by Manufacturers
3.2.1 Global Primary Biliary Cirrhosis Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Primary Biliary Cirrhosis Drug Revenue in 2024
3.3 Global Primary Biliary Cirrhosis Drug Sales Price by Manufacturers
3.4 Global Key Players of Primary Biliary Cirrhosis Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Product Offered and Application
3.8 Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Primary Biliary Cirrhosis Drug Sales Quantity by Type
4.1.1 Global Primary Biliary Cirrhosis Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Primary Biliary Cirrhosis Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Primary Biliary Cirrhosis Drug Revenue by Type
4.2.1 Global Primary Biliary Cirrhosis Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Primary Biliary Cirrhosis Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2018-2034)
4.3 Global Primary Biliary Cirrhosis Drug Price by Type
4.3.1 Global Primary Biliary Cirrhosis Drug Price by Type (2018-2023)
4.3.2 Global Primary Biliary Cirrhosis Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Primary Biliary Cirrhosis Drug Sales Quantity by Application
5.1.1 Global Primary Biliary Cirrhosis Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Primary Biliary Cirrhosis Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Primary Biliary Cirrhosis Drug Revenue by Application
5.2.1 Global Primary Biliary Cirrhosis Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Primary Biliary Cirrhosis Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2018-2034)
5.3 Global Primary Biliary Cirrhosis Drug Price by Application
5.3.1 Global Primary Biliary Cirrhosis Drug Price by Application (2018-2023)
5.3.2 Global Primary Biliary Cirrhosis Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Primary Biliary Cirrhosis Drug Sales by Company
6.1.1 North America Primary Biliary Cirrhosis Drug Revenue by Company (2018-2023)
6.1.2 North America Primary Biliary Cirrhosis Drug Sales Quantity by Company (2018-2023)
6.2 North America Primary Biliary Cirrhosis Drug Market Size by Type
6.2.1 North America Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Primary Biliary Cirrhosis Drug Revenue by Type (2018-2034)
6.3 North America Primary Biliary Cirrhosis Drug Market Size by Application
6.3.1 North America Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Primary Biliary Cirrhosis Drug Revenue by Application (2018-2034)
6.4 North America Primary Biliary Cirrhosis Drug Market Size by Country
6.4.1 North America Primary Biliary Cirrhosis Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Primary Biliary Cirrhosis Drug Revenue by Country (2018-2034)
6.4.3 North America Primary Biliary Cirrhosis Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Primary Biliary Cirrhosis Drug Sales by Company
7.1.1 Europe Primary Biliary Cirrhosis Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Primary Biliary Cirrhosis Drug Revenue by Company (2018-2023)
7.2 Europe Primary Biliary Cirrhosis Drug Market Size by Type
7.2.1 Europe Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Primary Biliary Cirrhosis Drug Revenue by Type (2018-2034)
7.3 Europe Primary Biliary Cirrhosis Drug Market Size by Application
7.3.1 Europe Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Primary Biliary Cirrhosis Drug Revenue by Application (2018-2034)
7.4 Europe Primary Biliary Cirrhosis Drug Market Size by Country
7.4.1 Europe Primary Biliary Cirrhosis Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Primary Biliary Cirrhosis Drug Revenue by Country (2018-2034)
7.4.3 Europe Primary Biliary Cirrhosis Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Primary Biliary Cirrhosis Drug Sales by Company
8.1.1 China Primary Biliary Cirrhosis Drug Sales Quantity by Company (2018-2023)
8.1.2 China Primary Biliary Cirrhosis Drug Revenue by Company (2018-2023)
8.2 China Primary Biliary Cirrhosis Drug Market Size by Type
8.2.1 China Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2034)
8.2.2 China Primary Biliary Cirrhosis Drug Revenue by Type (2018-2034)
8.3 China Primary Biliary Cirrhosis Drug Market Size by Application
8.3.1 China Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2034)
8.3.2 China Primary Biliary Cirrhosis Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Primary Biliary Cirrhosis Drug Sales by Company
9.1.1 APAC Primary Biliary Cirrhosis Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Primary Biliary Cirrhosis Drug Revenue by Company (2018-2023)
9.2 APAC Primary Biliary Cirrhosis Drug Market Size by Type
9.2.1 APAC Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Primary Biliary Cirrhosis Drug Revenue by Type (2018-2034)
9.3 APAC Primary Biliary Cirrhosis Drug Market Size by Application
9.3.1 APAC Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Primary Biliary Cirrhosis Drug Revenue by Application (2018-2034)
9.4 APAC Primary Biliary Cirrhosis Drug Market Size by Region
9.4.1 APAC Primary Biliary Cirrhosis Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Primary Biliary Cirrhosis Drug Revenue by Region (2018-2034)
9.4.3 APAC Primary Biliary Cirrhosis Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 AlbireoPharma
11.1.1 AlbireoPharma Company Information
11.1.2 AlbireoPharma Overview
11.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Products and Services
11.1.5 AlbireoPharma Primary Biliary Cirrhosis Drug SWOT Analysis
11.1.6 AlbireoPharma Recent Developments
11.2 CymaBay Therapeutics, Inc.
11.2.1 CymaBay Therapeutics, Inc. Company Information
11.2.2 CymaBay Therapeutics, Inc. Overview
11.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Products and Services
11.2.5 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug SWOT Analysis
11.2.6 CymaBay Therapeutics, Inc. Recent Developments
11.3 Dr. Falk Pharma GmbH
11.3.1 Dr. Falk Pharma GmbH Company Information
11.3.2 Dr. Falk Pharma GmbH Overview
11.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Products and Services
11.3.5 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug SWOT Analysis
11.3.6 Dr. Falk Pharma GmbH Recent Developments
11.4 Enanta Pharmaceuticals, Inc.
11.4.1 Enanta Pharmaceuticals, Inc. Company Information
11.4.2 Enanta Pharmaceuticals, Inc. Overview
11.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products and Services
11.4.5 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug SWOT Analysis
11.4.6 Enanta Pharmaceuticals, Inc. Recent Developments
11.5 GlaxoSmithKline Plc
11.5.1 GlaxoSmithKline Plc Company Information
11.5.2 GlaxoSmithKline Plc Overview
11.5.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Products and Services
11.5.5 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug SWOT Analysis
11.5.6 GlaxoSmithKline Plc Recent Developments
11.6 Intercept Pharmaceuticals, Inc.
11.6.1 Intercept Pharmaceuticals, Inc. Company Information
11.6.2 Intercept Pharmaceuticals, Inc. Overview
11.6.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products and Services
11.6.5 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug SWOT Analysis
11.6.6 Intercept Pharmaceuticals, Inc. Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Information
11.7.2 Johnson & Johnson Overview
11.7.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Products and Services
11.7.5 Johnson & Johnson Primary Biliary Cirrhosis Drug SWOT Analysis
11.7.6 Johnson & Johnson Recent Developments
11.8 MediGene AG
11.8.1 MediGene AG Company Information
11.8.2 MediGene AG Overview
11.8.3 MediGene AG Primary Biliary Cirrhosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 MediGene AG Primary Biliary Cirrhosis Drug Products and Services
11.8.5 MediGene AG Primary Biliary Cirrhosis Drug SWOT Analysis
11.8.6 MediGene AG Recent Developments
11.9 NGM Biopharmaceuticals, Inc.
11.9.1 NGM Biopharmaceuticals, Inc. Company Information
11.9.2 NGM Biopharmaceuticals, Inc. Overview
11.9.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products and Services
11.9.5 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug SWOT Analysis
11.9.6 NGM Biopharmaceuticals, Inc. Recent Developments
11.10 Virobay Inc.
11.10.1 Virobay Inc. Company Information
11.10.2 Virobay Inc. Overview
11.10.3 Virobay Inc. Primary Biliary Cirrhosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Virobay Inc. Primary Biliary Cirrhosis Drug Products and Services
11.10.5 Virobay Inc. Primary Biliary Cirrhosis Drug SWOT Analysis
11.10.6 Virobay Inc. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Primary Biliary Cirrhosis Drug Value Chain Analysis
12.2 Primary Biliary Cirrhosis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Primary Biliary Cirrhosis Drug Production Mode & Process
12.4 Primary Biliary Cirrhosis Drug Sales and Marketing
12.4.1 Primary Biliary Cirrhosis Drug Sales Channels
12.4.2 Primary Biliary Cirrhosis Drug Distributors
12.5 Primary Biliary Cirrhosis Drug Customers
13 Market Dynamics
13.1 Primary Biliary Cirrhosis Drug Industry Trends
13.2 Primary Biliary Cirrhosis Drug Market Drivers
13.3 Primary Biliary Cirrhosis Drug Market Challenges
13.4 Primary Biliary Cirrhosis Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Budesonide
Table 3. Major Manufacturers of FFP-104
Table 4. Major Manufacturers of GSK-2330672
Table 5. Major Manufacturers of MBX-8025
Table 6. Major Manufacturers of NGM-282
Table 7. Major Manufacturers of Others
Table 8. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Primary Biliary Cirrhosis Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Primary Biliary Cirrhosis Drug Revenue by Region (2018-2023) & (US$ Million)
Table 11. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2018-2023)
Table 12. Global Primary Biliary Cirrhosis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 13. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2024-2034)
Table 14. Global Primary Biliary Cirrhosis Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 15. Global Primary Biliary Cirrhosis Drug Sales by Region (2018-2023) & (K Pcs)
Table 16. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2018-2023)
Table 17. Global Primary Biliary Cirrhosis Drug Sales by Region (2024-2034) & (K Pcs)
Table 18. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2024-2034)
Table 19. Global Primary Biliary Cirrhosis Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 20. Global Primary Biliary Cirrhosis Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 21. Global Primary Biliary Cirrhosis Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 22. Global Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2018-2023)
Table 23. Global Primary Biliary Cirrhosis Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 24. Global Key Players of Primary Biliary Cirrhosis Drug, Industry Ranking, 2021 VS 2024
Table 25. Global Primary Biliary Cirrhosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Primary Biliary Cirrhosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Biliary Cirrhosis Drug as of 2024)
Table 27. Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Manufacturing Base Distribution and Headquarters
Table 28. Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Product Offered and Application
Table 29. Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Date of Enter into This Industry
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 32. Global Primary Biliary Cirrhosis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 33. Global Primary Biliary Cirrhosis Drug Sales Quantity Share by Type (2018-2023)
Table 34. Global Primary Biliary Cirrhosis Drug Sales Quantity Share by Type (2024-2034)
Table 35. Global Primary Biliary Cirrhosis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 36. Global Primary Biliary Cirrhosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 37. Global Primary Biliary Cirrhosis Drug Revenue Share by Type (2018-2023)
Table 38. Global Primary Biliary Cirrhosis Drug Revenue Share by Type (2024-2034)
Table 39. Primary Biliary Cirrhosis Drug Price by Type (2018-2023) & (USD/Pcs)
Table 40. Global Primary Biliary Cirrhosis Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 41. Global Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 42. Global Primary Biliary Cirrhosis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 43. Global Primary Biliary Cirrhosis Drug Sales Quantity Share by Application (2018-2023)
Table 44. Global Primary Biliary Cirrhosis Drug Sales Quantity Share by Application (2024-2034)
Table 45. Global Primary Biliary Cirrhosis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 46. Global Primary Biliary Cirrhosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 47. Global Primary Biliary Cirrhosis Drug Revenue Share by Application (2018-2023)
Table 48. Global Primary Biliary Cirrhosis Drug Revenue Share by Application (2024-2034)
Table 49. Primary Biliary Cirrhosis Drug Price by Application (2018-2023) & (USD/Pcs)
Table 50. Global Primary Biliary Cirrhosis Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 51. North America Primary Biliary Cirrhosis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 52. North America Primary Biliary Cirrhosis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 53. North America Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 54. North America Primary Biliary Cirrhosis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 55. North America Primary Biliary Cirrhosis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 56. North America Primary Biliary Cirrhosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 57. North America Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 58. North America Primary Biliary Cirrhosis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 59. North America Primary Biliary Cirrhosis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 60. North America Primary Biliary Cirrhosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 61. North America Primary Biliary Cirrhosis Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 62. North America Primary Biliary Cirrhosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 63. North America Primary Biliary Cirrhosis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 64. North America Primary Biliary Cirrhosis Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 65. North America Primary Biliary Cirrhosis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 66. Europe Primary Biliary Cirrhosis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 67. Europe Primary Biliary Cirrhosis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 68. Europe Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 69. Europe Primary Biliary Cirrhosis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 70. Europe Primary Biliary Cirrhosis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 71. Europe Primary Biliary Cirrhosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 72. Europe Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 73. Europe Primary Biliary Cirrhosis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 74. Europe Primary Biliary Cirrhosis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 75. Europe Primary Biliary Cirrhosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 76. Europe Primary Biliary Cirrhosis Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 77. Europe Primary Biliary Cirrhosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 78. Europe Primary Biliary Cirrhosis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 79. Europe Primary Biliary Cirrhosis Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 80. Europe Primary Biliary Cirrhosis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 81. China Primary Biliary Cirrhosis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 82. China Primary Biliary Cirrhosis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 83. China Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 84. China Primary Biliary Cirrhosis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 85. China Primary Biliary Cirrhosis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 86. China Primary Biliary Cirrhosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 87. China Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 88. China Primary Biliary Cirrhosis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 89. China Primary Biliary Cirrhosis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 90. China Primary Biliary Cirrhosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 91. APAC Primary Biliary Cirrhosis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 92. APAC Primary Biliary Cirrhosis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 93. APAC Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 94. APAC Primary Biliary Cirrhosis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 95. APAC Primary Biliary Cirrhosis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 96. APAC Primary Biliary Cirrhosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 97. APAC Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 98. APAC Primary Biliary Cirrhosis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 99. APAC Primary Biliary Cirrhosis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 100. APAC Primary Biliary Cirrhosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 101. APAC Primary Biliary Cirrhosis Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 102. APAC Primary Biliary Cirrhosis Drug Revenue by Region (2018-2023) & (US$ Million)
Table 103. APAC Primary Biliary Cirrhosis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 104. APAC Primary Biliary Cirrhosis Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 105. APAC Primary Biliary Cirrhosis Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 106. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 107. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 109. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 110. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 113. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 114. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 117. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 118. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 119. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 120. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 121. AlbireoPharma Company Information
Table 122. AlbireoPharma Description and Overview
Table 123. AlbireoPharma Primary Biliary Cirrhosis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 124. AlbireoPharma Primary Biliary Cirrhosis Drug Product and Services
Table 125. AlbireoPharma Primary Biliary Cirrhosis Drug SWOT Analysis
Table 126. AlbireoPharma Recent Developments
Table 127. CymaBay Therapeutics, Inc. Company Information
Table 128. CymaBay Therapeutics, Inc. Description and Overview
Table 129. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 130. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product and Services
Table 131. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug SWOT Analysis
Table 132. CymaBay Therapeutics, Inc. Recent Developments
Table 133. Dr. Falk Pharma GmbH Company Information
Table 134. Dr. Falk Pharma GmbH Description and Overview
Table 135. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 136. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product and Services
Table 137. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug SWOT Analysis
Table 138. Dr. Falk Pharma GmbH Recent Developments
Table 139. Enanta Pharmaceuticals, Inc. Company Information
Table 140. Enanta Pharmaceuticals, Inc. Description and Overview
Table 141. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 142. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
Table 143. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug SWOT Analysis
Table 144. Enanta Pharmaceuticals, Inc. Recent Developments
Table 145. GlaxoSmithKline Plc Company Information
Table 146. GlaxoSmithKline Plc Description and Overview
Table 147. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 148. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product and Services
Table 149. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug SWOT Analysis
Table 150. GlaxoSmithKline Plc Recent Developments
Table 151. Intercept Pharmaceuticals, Inc. Company Information
Table 152. Intercept Pharmaceuticals, Inc. Description and Overview
Table 153. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 154. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
Table 155. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug SWOT Analysis
Table 156. Intercept Pharmaceuticals, Inc. Recent Developments
Table 157. Johnson & Johnson Company Information
Table 158. Johnson & Johnson Description and Overview
Table 159. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 160. Johnson & Johnson Primary Biliary Cirrhosis Drug Product and Services
Table 161. Johnson & Johnson Primary Biliary Cirrhosis Drug SWOT Analysis
Table 162. Johnson & Johnson Recent Developments
Table 163. MediGene AG Company Information
Table 164. MediGene AG Description and Overview
Table 165. MediGene AG Primary Biliary Cirrhosis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 166. MediGene AG Primary Biliary Cirrhosis Drug Product and Services
Table 167. MediGene AG Primary Biliary Cirrhosis Drug SWOT Analysis
Table 168. MediGene AG Recent Developments
Table 169. NGM Biopharmaceuticals, Inc. Company Information
Table 170. NGM Biopharmaceuticals, Inc. Description and Overview
Table 171. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 172. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
Table 173. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug SWOT Analysis
Table 174. NGM Biopharmaceuticals, Inc. Recent Developments
Table 175. Virobay Inc. Company Information
Table 176. Virobay Inc. Description and Overview
Table 177. Virobay Inc. Primary Biliary Cirrhosis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 178. Virobay Inc. Primary Biliary Cirrhosis Drug Product and Services
Table 179. Virobay Inc. Primary Biliary Cirrhosis Drug SWOT Analysis
Table 180. Virobay Inc. Recent Developments
Table 181. Key Raw Materials Lists
Table 182. Raw Materials Key Suppliers Lists
Table 183. Primary Biliary Cirrhosis Drug Distributors List
Table 184. Primary Biliary Cirrhosis Drug Customers List
Table 185. Primary Biliary Cirrhosis Drug Market Trends
Table 186. Primary Biliary Cirrhosis Drug Market Drivers
Table 187. Primary Biliary Cirrhosis Drug Market Challenges
Table 188. Primary Biliary Cirrhosis Drug Market Restraints
Table 189. Research Programs/Design for This Report
Table 190. Key Data Information from Secondary Sources
Table 191. Key Data Information from Primary Sources
List of Figures
Figure 1. Primary Biliary Cirrhosis Drug Product Picture
Figure 2. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Primary Biliary Cirrhosis Drug Market Share by Type in 2024 & 2034
Figure 4. Budesonide Product Picture
Figure 5. FFP-104 Product Picture
Figure 6. GSK-2330672 Product Picture
Figure 7. MBX-8025 Product Picture
Figure 8. NGM-282 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 11. Global Primary Biliary Cirrhosis Drug Market Share by Application in 2024 & 2034
Figure 12. Clinic
Figure 13. Hospital
Figure 14. Others
Figure 15. Primary Biliary Cirrhosis Drug Report Years Considered
Figure 16. Global Primary Biliary Cirrhosis Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 17. Global Primary Biliary Cirrhosis Drug Revenue 2018-2034 (US$ Million)
Figure 18. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 19. Global Primary Biliary Cirrhosis Drug Sales Quantity 2018-2034 (K Pcs)
Figure 20. Global Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Region (2018-2023)
Figure 21. Global Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Region (2024-2034)
Figure 22. North America Primary Biliary Cirrhosis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. North America Primary Biliary Cirrhosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. Europe Primary Biliary Cirrhosis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. Europe Primary Biliary Cirrhosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. China Primary Biliary Cirrhosis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. China Primary Biliary Cirrhosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. APAC Primary Biliary Cirrhosis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. APAC Primary Biliary Cirrhosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 31. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 32. The Top 10 and Top 5 Players Market Share by Primary Biliary Cirrhosis Drug Sales Quantity in 2024
Figure 33. The Top 10 and Top 5 Players Market Share by Primary Biliary Cirrhosis Drug Revenue in 2024
Figure 34. Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 35. Global Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 36. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2018-2034)
Figure 37. Global Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 38. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2018-2034)
Figure 39. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Company in 2024
Figure 40. North America Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Company in 2024
Figure 41. North America Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 42. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2018-2034)
Figure 43. North America Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 44. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2018-2034)
Figure 45. North America Primary Biliary Cirrhosis Drug Revenue Share by Country (2018-2034)
Figure 46. North America Primary Biliary Cirrhosis Drug Sales Quantity Share by Country (2018-2034)
Figure 47. U.S. Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Canada Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Europe Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Company in 2024
Figure 50. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Company in 2024
Figure 51. Europe Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 52. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2018-2034)
Figure 53. Europe Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 54. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2018-2034)
Figure 55. Europe Primary Biliary Cirrhosis Drug Revenue Share by Country (2018-2034)
Figure 56. Europe Primary Biliary Cirrhosis Drug Sales Quantity Share by Country (2018-2034)
Figure 57. Germany Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 58. France Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 59. U.K. Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 60. Italy Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Russia Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 62. China Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Company in 2024
Figure 63. China Primary Biliary Cirrhosis Drug Revenue Market Share by Company in 2024
Figure 64. China Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 65. China Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2018-2034)
Figure 66. China Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 67. China Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2018-2034)
Figure 68. APAC Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Company in 2024
Figure 69. APAC Primary Biliary Cirrhosis Drug Revenue Market Share by Company in 2024
Figure 70. APAC Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 71. APAC Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2018-2034)
Figure 72. APAC Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 73. APAC Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2018-2034)
Figure 74. APAC Primary Biliary Cirrhosis Drug Revenue Share by Region (2018-2034)
Figure 75. APAC Primary Biliary Cirrhosis Drug Sales Quantity Share by Region (2018-2034)
Figure 76. Japan Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 77. South Korea Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 78. China Taiwan Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Southeast Asia Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 80. India Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 81. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Company in 2024
Figure 82. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue Market Share by Company in 2024
Figure 83. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Sales Quantity Share by Country (2018-2034)
Figure 88. Middle East, Africa and Latin America Primary Biliary Cirrhosis Drug Revenue Share by Country (2018-2034)
Figure 89. Brazil Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Mexico Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Turkey Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Israel Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 93. GCC Countries Primary Biliary Cirrhosis Drug Revenue (2018-2034) & (US$ Million)
Figure 94. Primary Biliary Cirrhosis Drug Value Chain
Figure 95. Primary Biliary Cirrhosis Drug Production Process
Figure 96. Channels of Distribution (Direct Vs Distribution)
Figure 97. Distributors Profiles
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed